questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Indolizine
Indolizidines
Alcaloïdes indoliques
Alcaloïdes formés par condensation de sécologanine et de tryptamine
Alcaloïdes de Vinca
Vinblastine
Vinblastine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Vinblastine
Cancer
Diagnostic médical
Tests de laboratoire
Imagerie médicale
Vinblastine
Symptômes
2
Effets secondaires
Vinblastine
Nausées
Douleur
Vinblastine
Effets indésirables
Prévention
2
Prévention du cancer
Vinblastine
Traitement
Effets secondaires
Vinblastine
Médicaments antiémétiques
Traitements
2
Lymphome
Cancer du poumon
Vinblastine
Administration intraveineuse
Vinblastine
Traitement du cancer
Complications
2
Complications
Vinblastine
Infections
Moelle osseuse
Vinblastine
Dépression médullaire
Facteurs de risque
2
Facteurs de risque
Vinblastine
Maladies cardiaques
Vinblastine
Pédiatrie
Traitement du cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vinblastine : Questions médicales les plus fréquentes",
"headline": "Vinblastine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vinblastine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-10",
"dateModified": "2025-05-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vinblastine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Alcaloïdes de Vinca",
"url": "https://questionsmedicales.fr/mesh/D014748",
"about": {
"@type": "MedicalCondition",
"name": "Alcaloïdes de Vinca",
"code": {
"@type": "MedicalCode",
"code": "D014748",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vinblastine",
"alternateName": "Vinblastine",
"code": {
"@type": "MedicalCode",
"code": "D014747",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Christine Chevreau",
"url": "https://questionsmedicales.fr/author/Christine%20Chevreau",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Oncopole, Toulouse, France."
}
},
{
"@type": "Person",
"name": "Stéphane Culine",
"url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Culine",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr."
}
},
{
"@type": "Person",
"name": "Gwenaelle Gravis",
"url": "https://questionsmedicales.fr/author/Gwenaelle%20Gravis",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France."
}
},
{
"@type": "Person",
"name": "Florence Joly",
"url": "https://questionsmedicales.fr/author/Florence%20Joly",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, François Baclesse Cancer Center, Caen, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The neuropeptide landscape of human prefrontal cortex.",
"datePublished": "2022-08-10",
"url": "https://questionsmedicales.fr/article/35947618",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1073/pnas.2123146119"
}
},
{
"@type": "ScholarlyArticle",
"name": "Do we understand the prefrontal cortex?",
"datePublished": "2022-11-08",
"url": "https://questionsmedicales.fr/article/36344701",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00429-022-02587-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Generalizing the control architecture of the lateral prefrontal cortex.",
"datePublished": "2022-10-18",
"url": "https://questionsmedicales.fr/article/36265793",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.nlm.2022.107688"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neural signature of flexible coding in prefrontal cortex.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36161948",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1073/pnas.2200400119"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prefrontal cortex as a key node in arousal circuitry.",
"datePublished": "2022-08-19",
"url": "https://questionsmedicales.fr/article/35995629",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.tins.2022.07.002"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Indolizine",
"item": "https://questionsmedicales.fr/mesh/D007212"
},
{
"@type": "ListItem",
"position": 6,
"name": "Indolizidines",
"item": "https://questionsmedicales.fr/mesh/D054836"
},
{
"@type": "ListItem",
"position": 7,
"name": "Alcaloïdes indoliques",
"item": "https://questionsmedicales.fr/mesh/D026121"
},
{
"@type": "ListItem",
"position": 8,
"name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine",
"item": "https://questionsmedicales.fr/mesh/D046948"
},
{
"@type": "ListItem",
"position": 9,
"name": "Alcaloïdes de Vinca",
"item": "https://questionsmedicales.fr/mesh/D014748"
},
{
"@type": "ListItem",
"position": 10,
"name": "Vinblastine",
"item": "https://questionsmedicales.fr/mesh/D014747"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vinblastine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vinblastine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vinblastine",
"description": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?\nQuels tests précèdent l'administration de vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Prefrontal+Cortex#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vinblastine",
"description": "Quels sont les effets secondaires courants de la vinblastine ?\nLa vinblastine provoque-t-elle des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Prefrontal+Cortex#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vinblastine",
"description": "La vinblastine a-t-elle un rôle préventif dans le cancer ?\nPeut-on prévenir les effets secondaires de la vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Prefrontal+Cortex#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vinblastine",
"description": "Dans quels types de cancer la vinblastine est-elle utilisée ?\nComment la vinblastine est-elle administrée ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Prefrontal+Cortex#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vinblastine",
"description": "Quelles complications peuvent survenir avec la vinblastine ?\nLa vinblastine peut-elle affecter la moelle osseuse ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Prefrontal+Cortex#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vinblastine",
"description": "Qui est à risque d'effets indésirables avec la vinblastine ?\nLes enfants peuvent-ils prendre de la vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Prefrontal+Cortex#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués."
}
},
{
"@type": "Question",
"name": "Quels tests précèdent l'administration de vinblastine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants de la vinblastine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux."
}
},
{
"@type": "Question",
"name": "La vinblastine provoque-t-elle des douleurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "La vinblastine a-t-elle un rôle préventif dans le cancer ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la vinblastine est un traitement et ne prévient pas le développement du cancer."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets secondaires de la vinblastine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine."
}
},
{
"@type": "Question",
"name": "Dans quels types de cancer la vinblastine est-elle utilisée ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule."
}
},
{
"@type": "Question",
"name": "Comment la vinblastine est-elle administrée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la vinblastine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des infections, des saignements et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "La vinblastine peut-elle affecter la moelle osseuse ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets indésirables avec la vinblastine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru."
}
},
{
"@type": "Question",
"name": "Les enfants peuvent-ils prendre de la vinblastine ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 05/05/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Publications dans "Vinblastine" :
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020-07-30
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.
British journal of haematology
2018-12-28
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
4 publications dans cette catégorie
Affiliations :
Department of Medicine, Oncopole, Toulouse, France.
Publications dans "Vinblastine" :
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
The Lancet. Oncology
2019-07-19
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, François Baclesse Cancer Center, Caen, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Jean Perrin Cancer Center, Clermont-Ferrand, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Pathology, René Huguenin Curie Institute, Saint Cloud, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
2 publications dans cette catégorie
Affiliations :
Programme in Developmental and Stem Cell Biology, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Plant Production Department, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology, Jena, Germany.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Massachusetts General Hospital Cancer Center, Boston, MA.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Small Animal Clinical Sciences, Department of Veterinary Anatomy Physiology and Pathology, Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Chester High Rd, Neston CH64 7TE, UK.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Rehabilitation Medicine, Nagoya University Hospital, Nagoya, Japan.
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland; Department of Applied Pharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland.
Publications dans "Vinblastine" :
Human prefrontal cortex (hPFC) is a complex brain region involved in cognitive and emotional processes and several psychiatric disorders. Here, we present an overview of the distribution of the peptid...
Many suggestions have been made as to the functions of the prefrontal (PF) cortex. However, they involve labelling areas using psychological terminology. But what we need to know is how the PF cortex ...
Cognitive control guides non-habitual, goal directed behaviors allowing us to flexibly adapt to ongoing demands. Previous work has suggested that multiple cognitive control processes exist that can be...
The ability of prefrontal cortex to quickly encode novel associations is crucial for adaptive behavior and central to working memory. Fast Hebbian changes in synaptic strength permit forming new assoc...
The role of the prefrontal cortex (PFC) in the mechanism of consciousness is a matter of active debate. Most theoretical and empirical investigations have focused on whether the PFC is critical for th...
To navigate effectively, we must represent information about our location in the environment. Traditional research highlights the role of the hippocampal complex in this process. Spurred by recent res...
Distraction reflects a drift of attention away from the task at hand towards task-irrelevant external or internal information (mind-wandering). The right posterior parietal cortex (PPC) and the medial...
Exploring the neural mechanisms of awareness is a fundamental task of cognitive neuroscience. There is an ongoing dispute regarding the role of the prefrontal cortex (PFC) in the emergence of awarenes...
Previous studies have associated brain abnormalities in people with fibromyalgia with accelerated brain ageing. The prefrontal cortex is located in the anterior pole of the mammalian brain. It is defi...
This study aimed to evaluate the volumetric differences in the prefrontal cortex subfields between healthy women and women with fibromyalgia using magnetic resonance imaging (MRI) and controlling for ...
A total of 47 women with fibromyalgia (recruited from a fibromyalgia local association) and 43 healthy women (retrieved from the Open Access Series of Imaging Studies database) participated in this cr...
Volume of all prefrontal cortex regions decreased with each year of age. Healthy women showed higher volume in all the prefrontal cortex subfields than women with fibromyalgia. Regarding partial corre...
Women with fibromyalgia showed reduced volume in the right caudal middle frontal gyrus, rostral middle frontal gyrus, left inferior frontal gyrus pars opercularis, inferior frontal gyrus pars triangul...
Work in computational psychiatry suggests that mood disorders may stem from aberrant reinforcement learning processes. Specifically, it has been proposed that depressed individuals believe that negati...